Immunovant: Best-In-Class Ambitions, Still Unproven [Seeking Alpha]
Immunovant, Inc. (IMVT)
Company Research
Source: Seeking Alpha
IMVT-1402 offers deeper IgG reduction, a cleaner safety profile, and convenient administration but must demonstrate clear clinical differentiation. The lead indication is Graves' disease, with pivotal data expected in 2027 and a potential launch in late 2028. I maintain a Hold rating on IMVT stock, preferring to await efficacy data in rheumatoid arthritis and Graves' disease before becoming more bullish. SergeyNivens/iStock via Getty Images Overview Immunovant, Inc.'s ( IMVT ) stock has advanced 18.7% since I analyzed it on October 31st. The company is developing a couple of FcRn inhibitors. The first one is batoclimab, and it is also developing a next-generation candidate, IMVT-1402. This article is intended to provide informational content and should not be viewed as an exhaustive analysis of the featured company. It should not be interpreted as personalized investment advice with regard to "Buy/Sell/Hold/Short/Long" recommendations. Financial models presented here, i
Show less
Read more
Impact Snapshot
Event Time:
IMVT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMVT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMVT alerts
High impacting Immunovant, Inc. news events
Weekly update
A roundup of the hottest topics
IMVT
News
- Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Immunovant (IMVT) had its "neutral" rating reaffirmed by The Goldman Sachs Group, Inc..MarketBeat
- Immunovant (IMVT) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM [Yahoo! Finance]Yahoo! Finance
- Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP [Yahoo! Finance]Yahoo! Finance
IMVT
Earnings
- 2/6/26 - Beat
IMVT
Sec Filings
- 4/10/26 - Form 4
- 4/10/26 - Form 4
- 4/10/26 - Form 4
- IMVT's page on the SEC website